Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

European Journal of Cancer

Volumn 46, Issue 15, 2010, Pages 2746-2752

  Santoro, Armando ^a   Rimassa, Lorenza ^a   Sobrero, Alberto F ^b   Citterio, Giovanni ^c   Sclafani, Francesco ^a   Carnaghi, Carlo ^a   Pessino, Anna ^b   Caprioni, Francesco ^b   Andretta, Valeria ^b   Tronconi, Maria Chiara ^a   Finocchiaro, Giovanna ^a   Rossoni, Gloria ^e   Zanoni, Angela ^c   Miggiano, Chiara ^c   Rizzardi, Gian Paolo ^e   Traversari, Catia ^e   Caligaris Cappio, Federico ^c,d   Lambiase, Antonio ^e   Bordignon, Claudio ^d,e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e MOLMED S P A   (Italy)

Author keywords

Colorectal cancer; NGR hTNF; Vascular targeting agent

Indexed keywords

ASPARTYLGLYCYLARGININE HUMAN TUMOR NECROSIS FACTOR FUSION PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER CONTROL; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL OBSTRUCTION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TENESMUS; TREATMENT RESPONSE; TREMOR; VALVULAR HEART DISEASE; VOMITING;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957197962     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.07.012     Document Type: Article

References (33)

1. E.A. Carswell, L.J. Old, and R.L. Kassel An endotoxin-induced serum factor that causes necrosis of tumors Proc Natl Acad Sci USA 72 1975 3666 3670
2. F.J. Lejeune, D. Lienard, M. Matter, and C. Ruegg Efficiency of recombinant human TNF in human cancer therapy Cancer Immun 6 2006 6 (Pubitemid 43853924)
3. P.J. Creaven, D.E. Brenner, and J.W. Cowens A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days Cancer Chemother Pharmacol 23 1989 186 191 (Pubitemid 19076605)
4. H. Gamm, A. Lindemann, R. Mertelsmann, and F. Herrmann Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy Eur J Cancer 27 1991 856 863
5. K. Kimura, T. Taguchi, and I. Urushizaki Phase I study of recombinant human tumor necrosis factor Cancer Chemother Pharmacol 20 1987 223 229 (Pubitemid 17163399)
6. A. Mittelman, C. Puccio, and E. Gafney A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion Invest New Drugs 10 1992 183 190
7. J.E. Schwartz, P. Scuderi, C. Wiggins, A. Rudolph, and E.M. Hersh A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy Biotherapy 1 1989 207 214 (Pubitemid 20196464)
8. B. Wiedenmann, P. Reichardt, and U. Rath Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas J Cancer Res Clin Oncol 115 1989 189 192 (Pubitemid 19109379)
9. D.L. Fraker, H.R. Alexander, and H.I. Pass Biologic therapy with TNF: systemic administration and isolation-perfusion V. De Vita, S. Hellman, S. Rosenberg, Biologic therapy of cancer: principles and practice 1995 JB Lippincott Co. Philadelphia (PA, USA) 329 345
10. D. Lienard, A.M. Eggermont, and H. Schraffordt Koops Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study Melanoma Res 4 Suppl. 1 1994 21 26 (Pubitemid 24144669)
11. A.M. Eggermont, H. Schraffordt Koops, and D. Lienard Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial J Clin Oncol. 14 1996 2653 2665 (Pubitemid 26329649)
12. H.R. Alexander, C.K. Brown, and D.L. Bartlett Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms Clin Cancer Res 4 1998 2357 2362
13. F. Curnis, A. Sacchi, and L. Borgna Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) Nat Biotechnol. 18 2000 1185 1190
14. A. Corti, and M. Ponzoni Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs Ann NY Acad Sci 1028 2004 104 112 (Pubitemid 40361814)
15. G. Colombo, F. Curnis, and G.M. De Mori Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif J Biol Chem 277 2002 47891 47897 (Pubitemid 36159317)
16. F. Curnis, G. Arrigoni, and A. Sacchi Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells Cancer Res 62 2002 867 874 (Pubitemid 34126966)
17. R. Rangel, Y. Sun, and L. Guzman-Rojas Impaired angiogenesis in aminopeptidase N-null mice PNAS 104 11 2007 4588 4593 (Pubitemid 47186269)
18. F. Curnis, A. Sacchi, and A. Corti Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration J Clin Invest 110 2002 475 482 (Pubitemid 34919701)
19. H.W.M. van Laarhoven, W. Fiedler, and I.M.E. Desar Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041) Clin Cancer Res 16 2010 1315 1323
20. V. Gregorc, C. Citterio, and G. Vitali Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours Eur J Cancer 46 2010 198 206
21. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis N Engl J Med 357 2007 2040 2048
22. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664 (Pubitemid 46797944)
23. Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol doi:10.1200/JCO.2008. 19.8168.
24. S.J. Cohen, C.J.A. Punt, and N. Iannotti Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer J Clin Oncol 26 2008 3213 3221
25. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
26. E.L. Kaplan, and P. Meier Nonparametric estimation of incomplete observations J Am Stat Assoc 53 1958 457 481
27. M. Schemper, and T.L. Smith A note on quantifying follow-up in studies of failure time Control Clin Trials 17 1996 343 346 (Pubitemid 26342716)
28. D.R. Cox Regression models and life tables J R Stat Soc B 34 1972 187 220
29. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 2005 423 436
30. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
31. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
32. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544
33. A. Sacchi, A. Gasparri, and C. Gallo-Stampino Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha Clin Cancer Res 12 2006 175 182 (Pubitemid 43166192)